modelTavaborole
Extends from Pharmacolibrary.Drugs.ATC.D.D01AE24.
Information
| name: | Tavaborole | |
| ATC code: | D01AE24 | route: | topical |
| compartments: | 1 | |
| dosage: | 444 | mg |
| volume of distribution: | 22 | L |
| clearance: | 1.8 | L/h |
| other parameters in model implementation | ||
Tavaborole is a topical antifungal agent used to treat onychomycosis (fungal infection of the toenails or fingernails) in adults. It acts by inhibiting leucyl-tRNA synthetase, thereby disrupting protein synthesis in fungal cells. It is an FDA-approved treatment for onychomycosis of the toenails caused by Trichophyton rubrum or Trichophyton mentagrophytes.
Pharmacokinetics
Pharmacokinetic parameters estimated in healthy adults based on available FDA label and review information. No published studies report quantitative compartmental pharmacokinetic models for tavaborole in humans.
References
Gregoriou, S, et al., & Rigopoulos, D (2022). Novel and Investigational Treatments for Onychomycosis. Journal of fungi (Basel, Switzerland) 8(10) –. DOI:10.3390/jof8101079 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36294644
Rich, P, et al., & Crook, TJ (2019). Tavaborole 5% Topical Solution for the Treatment of Toenail Onychomycosis in Pediatric Patients: Results from a Phase 4 Open-Label Study. Journal of drugs in dermatology : JDD 18(2) 190–195. PUBMED:https://pubmed.ncbi.nlm.nih.gov/30811142
Gupta, AK, & Studholme, C (2016). Novel investigational therapies for onychomycosis: an update. Expert opinion on investigational drugs 25(3) 297–305. DOI:10.1517/13543784.2016.1142529 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26765142
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)